BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures

BMO Capital reduced its 2025 Wegovy income estimation to DKK 77.8 billion, down from DKK 79.8 billion, compared with a statement forecast of DKK 78.4 billion. Despite favorable tailwinds, including the CVS exclusivity agreement, pressures similar the anticipated QoQ pricing proceed to exist, the steadfast noted. That said, BMO Capital estimates a comparatively level 2026 U.S. medicine measurement compared with 2025 levels, which would pb to antagonistic YoY U.S. nett income growth.

Cherries/Shutterstock.com

Three days earlier, Reuters reported that the company’s Wegovy cause was prescribed implicit 18,000 times successful the U.S. during the archetypal afloat week pursuing its launch. The study cited James Gordon from Barclays, who said,

“The aboriginal oral Wegovy motorboat information is precise strong, albeit successful a present acold amended established obesity marketplace versus gathering the obesity market.”

Novo Nordisk A/S (NYSE:NVO) is simply a Denmark-based institution that specializes successful pharmaceutical products. Founded successful 1923, the elephantine operates done 2 segments: Diabetes and Obesity Care and Rare Disease.

While we admit the imaginable of NVO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.